NCT02997761View on ClinicalTrials.gov

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

February 28, 2025

Study Completion Date

September 30, 2025

Conditions
Adult B Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive
Interventions
BIOLOGICAL

Blinatumomab

Given IV

DRUG

Ibrutinib

Given PO

Trial Locations (1)

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (1)

Pharmacyclics LLC.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Pharmacyclics LLC.

INDUSTRY

lead

Brian Jonas

OTHER

NCT02997761 - Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter